{"success":true,"data":{"pressRelease":{"id":"139572","rtpr_id":"nNFC1j4qXF-20260909","ticker":"MRVL","exchange":"","all_tickers":["MRVL"],"title":"Marvel Biosciences Announces Extension to Closing Date of Private Placement","author":"Newsfile Corp","published_at":"2026-09-09T18:31:48.710Z","article_body":"Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences\nCorp. (TSXV: MRVL) (OTCQB: MBCOF) (\"Marvel\" or the \"Company\") announces that\nit has received approval from the TSX Venture Exchange (\"TSXV\") to extend the\nclosing deadline of its previously announced private placement (see July 16,\n2026 and August 19, 2026 press releases) (the \"Offering\"). The deadline by\nwhich the Company must file its final closing materials with the TSXV has been\nextended from August 31, 2026 to September 14, 2026. All other terms and\nconditions of the Offering remain unchanged.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as the\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nAbout Marvel Biosciences Corp.\n\nMarvel Biosciences Corp., and its wholly owned subsidiary, Marvel\nBiotechnology Inc., is a Calgary‐based pre‐ clinical stage pharmaceutical\ndevelopment biotechnology company that utilizes a \"drug redevelopment\"\napproach to drug development. Historically, when a new class of drug is\ndeveloped, it is optimized for a particular target, but typically only\napproved for a specific disease. Often, a new disease is identified which\ninvolves the same target, however, pending the remaining patent life, the\noriginally approved drug may not have sufficient time left for it to be\ncommercially viable to be developed for the new disease indication. Marvel\ndevelops new synthetic chemical derivatives of the original approved drug for\nthe new disease indication. Patent protection is sought, as the new potential\nasset is developed by the Company. The Company believes the business model\nresults in significantly less risk, cost and time to develop its assets\ncompared to traditional biotechnology companies.\n\nMarvel Biotechnology Inc. has currently developed several new chemical\nentities, using synthetic chemical derivatives of known, off‐patent drugs,\nthat inhibit the A2a adenosine receptor with application to neurological\ndiseases (depression & anxiety, Alzheimer's, ADHD), and the non‐neurological\nconditions of cancer and non‐ alcoholic steatohepatitis. Marvel is also\nexploring additional undisclosed targets to expand its asset pipeline.\n\nContact Information:\nMarvel Biosciences Corp.\nJ. Roderick (Rod) Matheson, Chief Executive Officer or Dr. Mark Williams,\nPresident, and Chief Science Officer \nTel: 403 770 2469\nEmail: info@marvelbiosciences.com\n\nForward-Looking Statements\nThis news release contains \"forward‐looking information\" within the meaning\nof applicable Canadian securities legislation. All statements, other than\nstatements of historical fact, included herein are forward‐looking\ninformation. In particular, this news release contains forward‐looking\ninformation regarding: the Offering, the potential use of proceeds of the\nOffering, the closing date for the Offering, the business of the Company,\nincluding future plans and objectives. There can be no assurance that such\nforward‐looking information will prove to be accurate, and actual results\nand future events could differ materially from those anticipated in such\nforward‐looking information. This forward‐looking information reflects\nMarvel's current beliefs and is based on information currently available to\nMarvel and on assumptions Marvel believes are reasonable. These assumptions\ninclude, but are not limited to: the underlying value of Marvel and its Common\nShares, TSX Venture Exchange approval of the Offering; Marvel's current and\ninitial understanding and analysis of its projects and the development\nrequired for such projects; the costs of Marvel's projects; Marvel's general\nand administrative costs remaining constant; and the market acceptance of\nMarvel's business strategy. Forward‐looking information is subject to known\nand unknown risks, uncertainties and other factors that may cause the actual\nresults, level of activity, performance or achievements of Marvel to be\nmaterially different from those expressed or implied by such forward‐looking\ninformation. Such risks and other factors may include, but are not limited to:\ngeneral business, economic, competitive, political and social uncertainties;\nindustry condition; general capital market conditions and market prices for\nsecurities; delay or failure to receive board or regulatory approvals; the\nactual results of future operations; competition; changes in legislation\naffecting Marvel; the timing and availability of external financing on\nacceptable terms; and lack of qualified, skilled labour or loss of key\nindividuals. A description of additional risk factors that may cause actual\nresults to differ materially from forward‐looking information can be found\nin Marvel's disclosure documents on the SEDAR+ website at www.sedarplus.ca.\nAlthough Marvel has attempted to identify important factors that could cause\nactual results to differ materially from those contained in forward‐looking\ninformation, there may be other factors that cause results not to be as\nanticipated, estimated or intended. Readers are cautioned that the foregoing\nlist of factors is not exhaustive. Readers are further cautioned not to place\nundue reliance on forward‐looking information as there can be no assurance\nthat the plans, intentions or expectations upon which they are placed will\noccur. Forward‐looking information contained in this news release is\nexpressly qualified by this cautionary statement. The forward‐looking\ninformation contained in this news release represents the expectations of\nMarvel as of the date of this news release and, accordingly, is subject to\nchange after such date. However, Marvel expressly disclaims any intention or\nobligation to update or revise any forward‐looking information, whether as a\nresult of new information, future events or otherwise, except as expressly\nrequired by applicable securities law.\n\nNot for distribution to U.S. newswire services or dissemination in the United\nStates\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/313681","article_body_html":"","raw_payload":{"data":{"id":"nNFC1j4qXF-20260909","title":"Marvel Biosciences Announces Extension to Closing Date of Private Placement","author":"Newsfile Corp","ticker":"MRVL","created":"2026-09-09T18:31:48.710Z","tickers":["MRVL"],"exchange":"","article_body":"Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences\nCorp. (TSXV: MRVL) (OTCQB: MBCOF) (\"Marvel\" or the \"Company\") announces that\nit has received approval from the TSX Venture Exchange (\"TSXV\") to extend the\nclosing deadline of its previously announced private placement (see July 16,\n2026 and August 19, 2026 press releases) (the \"Offering\"). The deadline by\nwhich the Company must file its final closing materials with the TSXV has been\nextended from August 31, 2026 to September 14, 2026. All other terms and\nconditions of the Offering remain unchanged.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as the\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nAbout Marvel Biosciences Corp.\n\nMarvel Biosciences Corp., and its wholly owned subsidiary, Marvel\nBiotechnology Inc., is a Calgary‐based pre‐ clinical stage pharmaceutical\ndevelopment biotechnology company that utilizes a \"drug redevelopment\"\napproach to drug development. Historically, when a new class of drug is\ndeveloped, it is optimized for a particular target, but typically only\napproved for a specific disease. Often, a new disease is identified which\ninvolves the same target, however, pending the remaining patent life, the\noriginally approved drug may not have sufficient time left for it to be\ncommercially viable to be developed for the new disease indication. Marvel\ndevelops new synthetic chemical derivatives of the original approved drug for\nthe new disease indication. Patent protection is sought, as the new potential\nasset is developed by the Company. The Company believes the business model\nresults in significantly less risk, cost and time to develop its assets\ncompared to traditional biotechnology companies.\n\nMarvel Biotechnology Inc. has currently developed several new chemical\nentities, using synthetic chemical derivatives of known, off‐patent drugs,\nthat inhibit the A2a adenosine receptor with application to neurological\ndiseases (depression & anxiety, Alzheimer's, ADHD), and the non‐neurological\nconditions of cancer and non‐ alcoholic steatohepatitis. Marvel is also\nexploring additional undisclosed targets to expand its asset pipeline.\n\nContact Information:\nMarvel Biosciences Corp.\nJ. Roderick (Rod) Matheson, Chief Executive Officer or Dr. Mark Williams,\nPresident, and Chief Science Officer \nTel: 403 770 2469\nEmail: info@marvelbiosciences.com\n\nForward-Looking Statements\nThis news release contains \"forward‐looking information\" within the meaning\nof applicable Canadian securities legislation. All statements, other than\nstatements of historical fact, included herein are forward‐looking\ninformation. In particular, this news release contains forward‐looking\ninformation regarding: the Offering, the potential use of proceeds of the\nOffering, the closing date for the Offering, the business of the Company,\nincluding future plans and objectives. There can be no assurance that such\nforward‐looking information will prove to be accurate, and actual results\nand future events could differ materially from those anticipated in such\nforward‐looking information. This forward‐looking information reflects\nMarvel's current beliefs and is based on information currently available to\nMarvel and on assumptions Marvel believes are reasonable. These assumptions\ninclude, but are not limited to: the underlying value of Marvel and its Common\nShares, TSX Venture Exchange approval of the Offering; Marvel's current and\ninitial understanding and analysis of its projects and the development\nrequired for such projects; the costs of Marvel's projects; Marvel's general\nand administrative costs remaining constant; and the market acceptance of\nMarvel's business strategy. Forward‐looking information is subject to known\nand unknown risks, uncertainties and other factors that may cause the actual\nresults, level of activity, performance or achievements of Marvel to be\nmaterially different from those expressed or implied by such forward‐looking\ninformation. Such risks and other factors may include, but are not limited to:\ngeneral business, economic, competitive, political and social uncertainties;\nindustry condition; general capital market conditions and market prices for\nsecurities; delay or failure to receive board or regulatory approvals; the\nactual results of future operations; competition; changes in legislation\naffecting Marvel; the timing and availability of external financing on\nacceptable terms; and lack of qualified, skilled labour or loss of key\nindividuals. A description of additional risk factors that may cause actual\nresults to differ materially from forward‐looking information can be found\nin Marvel's disclosure documents on the SEDAR+ website at www.sedarplus.ca.\nAlthough Marvel has attempted to identify important factors that could cause\nactual results to differ materially from those contained in forward‐looking\ninformation, there may be other factors that cause results not to be as\nanticipated, estimated or intended. Readers are cautioned that the foregoing\nlist of factors is not exhaustive. Readers are further cautioned not to place\nundue reliance on forward‐looking information as there can be no assurance\nthat the plans, intentions or expectations upon which they are placed will\noccur. Forward‐looking information contained in this news release is\nexpressly qualified by this cautionary statement. The forward‐looking\ninformation contained in this news release represents the expectations of\nMarvel as of the date of this news release and, accordingly, is subject to\nchange after such date. However, Marvel expressly disclaims any intention or\nobligation to update or revise any forward‐looking information, whether as a\nresult of new information, future events or otherwise, except as expressly\nrequired by applicable securities law.\n\nNot for distribution to U.S. newswire services or dissemination in the United\nStates\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/313681"},"type":"article","timestamp":"2026-09-09T18:31:48.77635455Z","server_sent_at_ms":1788978708776},"received_at":"2026-09-09T18:31:48.860Z","source_url":"https://www.newsfilecorp.com/release/313681"},"analysis":{"id":"128408","press_release_id":"139572","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Private placement closing deadline extended past its original August 31, 2026 date following two prior offering press releases -- may signal slower-than-expected subscription closing","Pre-revenue micro-cap dependent on completion of this financing to fund its pre-clinical pipeline"],"eventType":"offering","narrative":"Marvel Biosciences received TSX Venture Exchange approval to extend the closing deadline of its previously announced private placement from August 31, 2026 to September 14, 2026.\n\nAll other terms and conditions of the Offering remain unchanged; the placement was previously covered in July 16, 2026 and August 19, 2026 press releases.\n\nMarvel is a Calgary-based pre-clinical biotech using a drug-redevelopment model, developing synthetic derivatives of off-patent drugs that inhibit the A2a adenosine receptor for neurological conditions and cancer/NASH.\n\nCompleting this financing matters for a pre-revenue issuer's runway, so the pushed-out closing date is worth tracking as a demand signal for the raise even though the extension itself is administrative.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap biotech slips private placement close to September 14 -- a financing-runway watch item rather than headline news."},"keyFigures":{"customDimensions":{"exchange":"TSX Venture Exchange","new_close_deadline":"September 14, 2026","prior_announcements":["July 16, 2026","August 19, 2026"],"prior_close_deadline":"August 31, 2026"}},"namedEntities":{"people":[{"name":"J. Roderick (Rod) Matheson","role":"Chief Executive Officer"},{"name":"Dr. Mark Williams","role":"President and Chief Science Officer"}],"products":[],"companies":[{"name":"Marvel Biosciences Corp.","ticker":"MRVL","relationship":"filer"},{"name":"Marvel Biotechnology Inc.","relationship":"wholly owned subsidiary"},{"name":"TSX Venture Exchange","relationship":"listing exchange / regulator"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Administrative extension of a previously announced private placement closing deadline, approved by the TSXV with all other terms unchanged. Relevant to a pre-revenue micro-cap's financing runway, but no new terms, size, or pricing disclosed."},"tickerRelevance":{"others":[{"ticker":"MBCOF","relevance":"same issuer, OTCQB listing"}],"primary":"MRVL"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"administrative offering extension","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"offering","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Marvel Biosciences received TSX Venture Exchange approval to extend the closing deadline of its previously announced private placement from August 31, 2026 to September 14, 2026.\n\nAll other terms and conditions of the Offering remain unchanged; the placement was previously covered in July 16, 2026 and August 19, 2026 press releases.\n\nMarvel is a Calgary-based pre-clinical biotech using a drug-redevelopment model, developing synthetic derivatives of off-patent drugs that inhibit the A2a adenosine receptor for neurological conditions and cancer/NASH.\n\nCompleting this financing matters for a pre-revenue issuer's runway, so the pushed-out closing date is worth tracking as a demand signal for the raise even though the extension itself is administrative.","key_figures":{"customDimensions":{"exchange":"TSX Venture Exchange","new_close_deadline":"September 14, 2026","prior_announcements":["July 16, 2026","August 19, 2026"],"prior_close_deadline":"August 31, 2026"}},"named_entities":{"people":[{"name":"J. Roderick (Rod) Matheson","role":"Chief Executive Officer"},{"name":"Dr. Mark Williams","role":"President and Chief Science Officer"}],"products":[],"companies":[{"name":"Marvel Biosciences Corp.","ticker":"MRVL","relationship":"filer"},{"name":"Marvel Biotechnology Inc.","relationship":"wholly owned subsidiary"},{"name":"TSX Venture Exchange","relationship":"listing exchange / regulator"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-09T18:32:27.718Z","global_importance":10,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"administrative offering extension","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":null,"modelName":"glm-5.3-flash"}}